Abstract Details

Title Medication Adherence with Interferon beta-1a Treatment Using an Electronic Injection Device: Data from a Prospective Scandinavian Non-Interventional Study (The Scansmart Study)

Topic MS and Related Diseases

Presentation(s) P01 - (-)

Poster/Presentation
Number 202

Objective

Background BACKGROUND: Relapsing remitting multiple sclerosis (RRMS) is the most common form of MS. Disease modifying drugs (DMDs) can help to control the course of MS. Medication adherence is important for long-term outcome. Rebismart® is an electronic injection device developed to be used with Rebif® (interferon (IFN) beta-1a). Rebismart® can accurately monitor patient adherence to IFN treatment over time.

Design/Methods DESIGN/METHODS: Prospective, single-arm, open-label, non-interventional multicentre Phase IV trial including 60 patients aged 18-65 years with RRMS, EDSS <6, who had used a DMD for >6 months prior to screening. Patients were seen at baseline and after 12 weeks when injection history was downloaded from Rebismart®. Adherence was defined as 100[times]the number of administered injections divided by the expected number of injections over 12 weeks. MSTCQ (items 13-23, 35 and 37-38) was administered at 12 weeks.

Results RESULTS: Mean age (SD) was 43.7(7.9), 83% female, year since MS diagnosis (SD) 6.7(4.5). Data on adherence were obtained from 54 of the 60 patients. Treatment adherence over 12 weeks was: <75%: N=3(6%), 75 to <80%: N=1(2%); 80 to <85%: N=1(2%); 85 to <90%: N=2(4%); 90 to <95%: N=6(11%); 95 to >100%: N=41(76%). Mean (SD) MSTCQ scores: flu-like symptoms subscale 7.4 (3.9), injection-site reactions subscale 10.3 (3.6), global side-effects subscale 5.0 (2.4).

Conclusions CONCLUSIONS: RRMS patients treated with Rebif® administrated with the electronic injection device Rebismart®, showed generally good adherence with almost 80% of patients taking nearly 90% of planned injections. Treatment with Rebismart® is generally well tolerated and can accurately monitor adherence to IFN beta-1a over time.

Authors/Disclosures
Elena Pedersen, PhD (AHUS HF) PRESENTER	No disclosure on file
Egon Stenager, MD (MS-Clinic, SV-Sygehus Esbjerg)	No disclosure on file
	No disclosure on file
	No disclosure on file
Jeffrey D. Rothstein, MD, PhD (Johns Hopkins University)	Dr. Rothstein has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Corcept Therapeutics. Dr. Rothstein has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Lilly Pharmaceuticasl. Dr. Rothstein has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for ALS Journal. The institution of Dr. Rothstein has received research support from ALSA. The institution of Dr. Rothstein has received research support from MDA. The institution of Dr. Rothstein has received research support from Target ALS. The institution of Dr. Rothstein has received research support from Maryland TEDCO. The institution of Dr. Rothstein has received research support from Dept of Defense. The institution of Dr. Rothstein has received research support from National Insitutes of Health. The institution of Dr. Rothstein has received research support from Corsalex. Dr. Rothstein has received intellectual property interests from a discovery or technology relating to health care.
	No disclosure on file
	No disclosure on file
David Olsen, MD (Merck Serono)	No disclosure on file
	No disclosure on file
Daniel Friedman, MD, FAAN (NYU Langone Medical Center)	The institution of Dr. Friedman has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Epilepsy Study Consortium (non-profit). Dr. Friedman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Meili Technology. Dr. Friedman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurelis. Dr. Friedman has stock in Neuroview Technology. The institution of Dr. Friedman has received research support from NIH. The institution of Dr. Friedman has received research support from CDC. The institution of Dr. Friedman has received research support from Epitel. The institution of Dr. Friedman has received research support from Neuropace. The institution of Dr. Friedman has received research support from Rapport Therapeutics. Dr. Friedman has received intellectual property interests from a discovery or technology relating to health care. Dr. Friedman has received intellectual property interests from a discovery or technology relating to health care. Dr. Friedman has received publishing royalties from a publication relating to health care. Dr. Friedman has received personal compensation in the range of $500-$4,999 for serving as a Speaker Honorarium with SK Life Sciences. Dr. Friedman has received personal compensation in the range of $500-$4,999 for serving as a Speaker Honorarium with AAN. Dr. Friedman has received personal compensation in the range of $500-$4,999 for serving as a Travel Reimbursement with Epilepsy Foundation of America.

��ɫ��

��ɫ��